Marie Sklodowska-Curie Actions Innovative Training Network
“Mass spectrometry training in protein lipoxidation analysis for inflammation”
Funded by EU, Horizon 2020
Marie Sklodowska Curie innovative training network MASSTRPLAN or “Mass spectrometry training network for protein lipid adduct analysis” is international consortium which unites 10 beneficiaries and 15 partners from 14 European countries, and represented by universities, clinics, hospitals as well as companies.
The aim of the consortium is to study molecular mechanisms of chronic inflammatory-based diseases using modern analytical instrumentations.
MASSTRPLAN aims to study molecular mechanisms of chronic inflammatory-based diseases using modern analytical instrumentations, such mass spectrometry, liquid chromatography, and fluorescence microscopy. Development and combination of modern analytical protocols gives us a chance to underpin the molecular mechanisms of pathogenesis. Better understanding of the disease processes at molecular level and availability of specific biomarkers for earlier diagnosis are extremely important for the improvement of the patient treatment and disease prognosis.
As a part of MASSTRPLAN our team works on two individual projects:
Identification and validation of modified lipids and proteins targets in cellular models of oxidative stress
Using different cellular models of oxidative stress we are aiming to develop and optimize sensitive and specific LC-MS protocols for identification of oxidized lipids and proteins in complex cellular extracts. Multi-Omics data on oxidized species are used for integration via systems biology approaches to evaluate their role on cellular functions. Obtained results are combined with evaluation of changes in cellular localization and function of molecular targets by fluorescence microscopy & mutagenesis.
Identification and quantification of potential oxidation related biomarkers in plasma samples from patients with inflammatory diseases
We are working on development of new analytical LC-MS protocols for biomarker discovery (label-free and label-dependent lipidomics and proteomics) in plasma samples from patients with inflammatory disorders (rheumatoid arthritis, type 2 diabetes). Identified biomarkers are used to design representative standards of lipoxidized peptides and applied in new quantitative MS based methods (MRM) for biomarker quantitation. Validated biomarkers will be used for development of diagnostic tools for translational and commercial applications (ELISA or MRM-based quantification assays).